Welcome to our dedicated page for AKTIS ONCOLOGY SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to aggregate U.S. regulatory filings for Aktis Oncology, Inc. (Nasdaq: AKTS), a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors. While specific SEC filings are not listed in the provided information, a Nasdaq-listed issuer such as Aktis Oncology would typically use SEC reports to describe its business, pipeline, risks, and capital structure in more detail.
Annual and quarterly reports, such as Forms 10-K and 10-Q when available, generally provide narrative and financial disclosure about companies like Aktis Oncology. For a clinical-stage radiopharmaceutical company, these documents often include descriptions of its miniprotein radioconjugate platform, targeted tumor types, clinical development plans, and factors that could affect its research and development activities.
Registration statements, such as the Form S-1 that Aktis Oncology reports was declared effective in connection with its initial public offering, offer additional background on the company’s history, founding, and the structure of its capital raising transactions. Aktis Oncology has stated that its common stock began trading on the Nasdaq Global Select Market under the ticker AKTS following the effectiveness of its Form S-1.
On this filings page, Stock Titan’s tools can be used to review such documents when they are available from the SEC’s EDGAR system. AI-powered summaries are designed to highlight key sections of lengthy filings, such as business descriptions, risk factors related to clinical development and radiopharmaceutical safety, and disclosures about collaborations like the company’s strategic relationship with Eli Lilly and Company.
Users interested in AKTS can use this page to monitor new filings as they appear, compare successive disclosures, and better understand how Aktis Oncology presents its radiopharmaceutical platform, pipeline candidates, and single operating segment focused on research and development in official regulatory documents.
Aktis Oncology Chief Operating Officer Shulamit Ron-Bigger reported her existing stock option holdings in a Form 3 insider ownership filing. The filing lists stock options to purchase 267,888 shares of common stock at $3.66 per share expiring on 10/30/2032, 18,697 shares at $4.95 expiring on 06/30/2034, 118,284 shares at $9.33 expiring on 10/10/2034, and 131,426 shares at $18 expiring on 01/07/2036, all held directly.
For three grants, 25% of the original option amount either has vested or is scheduled to vest on specific dates, with the remaining portions vesting in equal monthly installments over 48 months, as long as Ron-Bigger continues in service. This filing establishes her baseline equity position as an officer of Aktis Oncology.
Aktis Oncology director and 10% owner Todd Foley filed a Form 3 detailing his indirect and direct interests in the company’s securities as of January 8, 2026. Investment entities associated with him hold 597,391 shares of Series Seed Redeemable Convertible Preferred Stock, 2,688,270 shares of Series A Redeemable Convertible Preferred Stock, and 716,872 shares of Series B Redeemable Convertible Preferred Stock, each series convertible into common stock on a 3.8044‑for‑1 basis upon the closing of the company’s initial public offering. Foley disclaims beneficial ownership of these preferred shares except to the extent of his pecuniary interest. He also directly holds a stock option for 37,866 shares of common stock at an exercise price of $18 per share, vesting in equal monthly installments over 36 months starting January 8, 2026, conditioned on continued service.
Aktis Oncology, Inc. filed an initial Form 3 showing that its Chief Scientific Officer, Paul L. Feldman, beneficially owns 144,568 shares of common stock directly as of January 8, 2026.
He also holds several stock options to buy common stock: one option for 65,713 shares at an exercise price of $1.91 per share expiring on April 14, 2031, which has vested in full; an option for 119,248 shares at $3.66 per share expiring on November 15, 2032 that vests monthly after 25% vested on November 1, 2023; an option for 90,684 shares at $9.33 per share expiring on October 10, 2034 with similar monthly vesting after 25% vested on October 9, 2025; and an option for 131,246 shares at $18 per share expiring on January 7, 2036, with 25% scheduled to vest on January 8, 2027 and the remainder in monthly installments, all subject to his continuous service.
Aktis Oncology, Inc. Chief Medical Officer Akos Czibere filed an initial ownership report showing holdings of several stock options. These options give rights to buy common stock at exercise prices of $4.95 for 271,218 shares, $9.33 for 98,570 shares, $11.46 for 19,714 shares, and $18.00 for 131,426 shares, all held directly. Portions of the earlier grants vested on July 1, 2025 and October 9, 2025, with the remaining shares vesting in equal monthly installments, subject to continued service. Newer grants are scheduled to begin vesting with 25% cliffs on November 1, 2026 and January 8, 2027, followed by monthly vesting thereafter.
Aktis Oncology director Michael A. Sherman filed a report of his beneficial ownership of stock options in Aktis Oncology, Inc. On January 8, 2026, he held a stock option for 74,913 shares of common stock at an exercise price of $9.14, expiring on October 8, 2035. Twenty‑five percent of these shares vest on August 1, 2026, with the remainder vesting in equal monthly installments, subject to his continued service. He also held a second stock option for 18,933 shares at an exercise price of $18, expiring on January 7, 2036, which vests in full on January 8, 2027 if he remains in service.
Aktis Oncology, Inc. director Mary Thistle filed an initial ownership report showing she beneficially owns two stock option awards for common stock as of January 8, 2026. One option covers 74,913 shares at an exercise price of
Aktis Oncology, Inc. (AKTS) filed a Form 3 for EcoR1 Capital, LLC and Oleg Nodelman, identifying them as a director and 10% owners. The filing reports indirect beneficial ownership of Series A and Series B redeemable convertible preferred stock held through EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P., and EcoR1 Venture Opportunity Fund, L.P. These preferred shares are immediately exercisable, have no expiration date, and will automatically convert into common stock on a 3.8044-for-1 basis immediately before the closing of the company’s initial public offering, with amounts reflecting a 1-for-3.8044 reverse stock split effective January 2, 2026.
The Form 3 also discloses a director stock option for 37,866 shares of common stock at an exercise price of $18, beneficially owned solely by Mr. Nodelman. One‑thirty‑sixth of the option vests in monthly installments from January 8, 2026, subject to his continuous service. The reporting persons are filing jointly, but state they are not a group and disclaim beneficial ownership of the securities except to the extent of their pecuniary interests.
Vida Ventures II, LLC and Vida Ventures II-A, LLC filed an initial Form 3 as 10% owners of Aktis Oncology, Inc. (AKTS), reporting indirect holdings of the company’s preferred stock. The filing shows Series A and Series B Redeemable Convertible Preferred Stock that each convert into common stock on a 3.8044-for-1 basis with no expiration date. All shares of both preferred series will automatically convert into common stock immediately prior to the closing of Aktis Oncology’s initial public offering, without any additional payment. The shares are held through Vida Ventures II and Vida Ventures II-A, with management entities and committee members disclaiming beneficial ownership beyond their pecuniary interest.
Aktis Oncology, Inc. is offering 17,650,000 shares of common stock in an initial public offering, with an expected price range of $16.00 to $18.00 per share and a 30‑day underwriters’ option for up to 2,647,500 additional shares. The company expects about $274.5 million in net proceeds at a $17.00 midpoint, and 52,522,279 shares of common stock outstanding after the deal. Aktis is a clinical-stage radiopharmaceutical company developing miniprotein-based drugs targeting solid tumors, led by Nectin‑4 candidate [225Ac]Ac‑AKY‑1189 in a Phase 1b trial and B7‑H3 program [225Ac]Ac‑AKY‑2519 nearing an IND filing. Eli Lilly has indicated interest in purchasing approximately $100.0 million of stock in the IPO and previously paid $60.0 million upfront plus an equity investment in a discovery collaboration with milestones up to $1.2 billion. Aktis reported net losses of $44.0 million in 2024 and $48.6 million for the nine months ended September 30, 2025, with an accumulated deficit of $141.4 million and $246.2 million in cash, cash equivalents and marketable securities, which it believes will fund operations into 2029.